# US 2011/0212161 A1 · Treatment skin disorders

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2011/0212161 A1
- Document ID: US20110212161A1
- Status: Published application
- Kind: A1
- Application number: 13/021,063
- Filed: 2011-02-04
- Published: 2011-09-01
- Earliest claimed: 2002-04-26
- Assignees: Asan Laboratories Company (Cayman), Limited
- Inventors: Yih-Lin Chung; Nam-Mew Pui; Wei-Wei Chang
- Web page: https://patentgrep.com/patent/US20110212161A1

## CPC

- A61K 31/19: Carboxylic acids, e.g. valproic acid (salicylic acid A61K31/60)
- A61K 31/192: having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid {(cannabinoids A61K31/658)}
- A61K 31/196: the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
- A61K 31/4355: the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/10: Anti-acne agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Disclosed are a composition and a method for treating skin disorders, including rosacea, pityriasis rosea, erythema, rhinophyma, and rosacea-associated disorders including pimples, papules, pustules, and telangiectasia.

## Claims

### Claim 1

A method for treating a skin disorder, comprising administering to a subject in need thereof a composition containing an effective amount of a histone hyperacetylating agent or a pharmaceutically acceptable salt thereof, and a cosmetically or pharmaceutically acceptable carrier, wherein the disorder is selected from the group consisting of rosacea, pityriasis rosea, erythema, rhinophyma, and a rosacea-associated disorder that is pimple, papule, pustule, or telangiectasia.

### Claim 2 (depends on 1)

The method of claim 1, wherein the composition is a topical composition.

### Claim 3 (depends on 2)

The method of claim 2, wherein the histone hyperacetylating agent is a histone deacetylase inhibitor.

### Claim 4 (depends on 2)

The method of claim 2, wherein the histone hyperacetylating agent is trichostatin A or trichostatin C.

### Claim 5 (depends on 2)

The method of claim 2, wherein the histone hyperacetylating agent is oxamflatin, trapoxin A, FR901228, apicidin, HC-Toxin, WF27082, or chlamydocin.

### Claim 6 (depends on 2)

The method of claim 2, wherein the histone hyperacetylating agent is salicylihydroxamic acid, suberoylanilide hydroxamic acid, or azelaic bishydroxamic acid.

### Claim 7 (depends on 2)

The method of claim 2, wherein the histone hyperacetylating agent is azelaic-1-hydroxamate-9-an-ilide, M-carboxycinnamic acid bishydroxamide, 6-(3-chlorophenylureido) carpoic hydroxamic acid, MW2796, or MW2996.

### Claim 8 (depends on 2)

The method of claim 2, wherein the histone hyperacetylating agent is sodium butyrate, arginine butyrate, isovalerate, valerate, 4-phenylbutyrate, propionate, butrymide, isobutyramide, phenylacetate, 3-bromopropionate, valproic acid, valproate, or tributyrin.

### Claim 9 (depends on 2)

The method of claim 2, wherein the histone hyperacetylating agent is MS-27-275 or a 3′-amino derivative thereof.

### Claim 10 (depends on 2)

The method of claim 2, wherein the histone hyperacetylating agent is depudecin or scriptaid.

### Claim 11 (depends on 2)

The method of claim 2, wherein the composition is a cream, an ointment, a gel, a paste, a powder, an aqueous solution, a spray, a suspension, a dispersion, a salve, a lotion, a patch, a suppository, a liposome formulation, a mouth wash, an enema, an eye drop, an ear drop, a microcapsule formulation, or a nanocapsule formulation.

### Claim 12 (depends on 1)

The method of claim 1, wherein the method further comprises administering to the subject a second agent that is a cytokine, a cytokine antagonist, an interleukin, an interleukin antagonist, a growth factor, an angiogenic agent, an anti-histamine, an anti-fibrogenic agent, a vasoactive agent, an antibody, a conjugated antibody, an adenosine receptor agonist, a peroxisome proliferating activator receptor agonist, an anticholinergics, a non-steroid anti-inflammation drug, a steroid, an anti-oxidant agent, a vitamin, a leukotriene modifier, a mast cell inhibitor, an anti-IgE antibody, lidocaine, epinephrine, a selective serotonin reuptake inhibitor, a 5-hydroxytryptamine receptor antagonist, an antibiotics, a calcineurin inhibitor, an amino acid, a matrix metalloproteinase inhibitor, a DNA methylation inhibitor, collagenase, clostridium histolyticum, or combinations thereof.

### Claim 13 (depends on 12)

The method of claim 12, wherein the composition and the second agent are topically administered simultaneously or separately.

### Claim 14 (depends on 1)

The method of claim 1, wherein the disorder is rosacea.

### Claim 15 (depends on 14)

The method of claim 14, wherein the composition is a topical composition.

### Claim 16 (depends on 15)

The method of claim 15, wherein the histone hyperacetylating agent is sodium butyrate, arginine butyrate, isovalerate, valerate, 4-phenylbutyrate, propionate, butrymide, isobutyramide, phenylacetate, 3-bromopropionate, valproic acid, valproate, or tributyrin.

### Claim 17 (depends on 16)

The method of claim 16, wherein the histone hyperacetylating agent is sodium 4-phenylbutyrate.

### Claim 18 (depends on 1)

The method of claim 1, wherein the disorder is pityriasis rosea.

### Claim 19 (depends on 1)

The method of claim 1, wherein the disorder is erythema.

### Claim 20 (depends on 1)

The method of claim 1, wherein the disorder is rhinophyma.
